Holen Sie sich die Stockscreener-App
2.63
27.67%
0.57
Handel nachbörslich:
2.60
-0.03
-1.14%
Schlusskurs vom Vortag:
$2.06
Offen:
$2.03
24-Stunden-Volumen:
14.62M
Relative Volume:
1.35
Marktkapitalisierung:
$334.68M
Einnahmen:
Nettoeinkommen (Verlust:
$-57.09M
KGV:
-5.8224
EPS:
-0.4517
Netto-Cashflow:
$-51.43M
1W Leistung:
+21.20%
1M Leistung:
+172.26%
6M Leistung:
-13.20%
1J Leistung:
+171.13%
1-Tages-Spanne:
$1.97
$2.68
1-Wochen-Bereich:
$1.88
$2.68
52-Wochen-Spanne:
$0.8411
$4.3101
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Firmenname
Nautilus Biotechnology Inc
Sektor
Branche
Telefon
206-333-2001
Adresse
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
2.63 | 334.68M | 0 | -57.09M | -51.43M | -0.4517 |
VRTX
Vertex Pharmaceuticals Inc
|
501.95 | 127.22B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
226.89 | 90.58B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
782.04 | 80.51B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.61 | 51.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.17 | 41.87B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-29 | Eingeleitet | Roth Capital | Buy |
| 2026-09-09 | Eingeleitet | Leerink Partners | Outperform |
| 2024-12-05 | Herabstufung | Goldman | Neutral → Sell |
| 2024-06-27 | Eingeleitet | Guggenheim | Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2022-01-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-02 | Eingeleitet | Cowen | Outperform |
| 2021-08-04 | Eingeleitet | Goldman | Neutral |
| 2021-07-13 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Nautilus Biotechnology Inc Aktie (NAUT) Neueste Nachrichten
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026 - GlobeNewswire Inc.
Nautilus Biotechnology Files $300 Million Shelf Registration - Moomoo
NAUT Stock Price, Quote & News - Syfe
NAUT Stock Climbs As Wall Street Backs Voyager Platform - StocksToTrade
NAUT Stock Climbs As Bullish Coverage Backs Voyager Platform - timothysykes.com
Nautilus Biotechnology Inc. (NAUT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Nautilus Biotechnology NAUT Draws Bullish Analyst Wave - StocksToTrade
September 2026 Penny Stocks Worth Watching - Simply Wall Street
Roth/MKM initiates Nautilus Biotechnology stock with buy rating - Investing.com
Nautilus Biotechnology Establishes New At-The-Market Offering - The Globe and Mail
Andreessen Horowitz stake in Nautilus (NASDAQ: NAUT) falls below 5% - Stock Titan
Nautilus Biotechnology Establishes New At-The-Market Offering - TipRanks
Nautilus Biotechnology May Offer Up To $300 Million Of SecuritiesSEC Filing - TradingView
Nautilus Biotechnology Launches $125 Million ATM Program With TD Cowen; Agent Fee Up to 3% - TradingView
Nautilus Biotechnology (NASDAQ: NAUT) lines up new $300M fundraising capacity - Stock Titan
Nautilus Biotechnology Files $300 Million Shelf Registration - Yahoo Finance
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms - Investing News Network
Nautilus Biotechnology paper on tau proteoform analysis published in Nature Methods - Traders Union
Nautilus found 130 forms of a protein linked to Alzheimer’s. Some appeared in just 0.1% of samples. - Stock Titan
Nautilus Biotechnology (NAUT) Advances 3.81% to $0.96, Testing Move Toward Key $1.01 ResistanceWyckoff Accumulation - dars.gov.et
Nautilus Biotechnology heads to HUPO 2026 to unveil Voyager platform breakthroughs - Traders Union
Nautilus Biotechnology (NAUT) Advances 3.81% to $0.96, Testing Move Toward Key $1.01 ResistanceFactor Rotation - dars.gov.et
Nautilus Biotechnology (NAUT) Advances 3.81% to $0.96, Testing Move Toward Key $1.01 ResistanceRunaway Gap - dars.gov.et
Andreessen Horowitz sells Nautilus (NAUT) shares around $1 - Stock Titan
Nautilus (NAUT) Market: Finishes 8.30% Down at $0.88 in the Latest Session; Price Levels: the Session Ends Within the Reported Technical BoundariesValue Area Low - vinanet.vn
Nautilus (NAUT) Market: Finishes 8.30% Down at $0.88 in the Latest Session; Price Levels: the Session Ends Within the Reported Technical BoundariesCommon Gap - dars.gov.et
Nautilus (NAUT) Financial Results: Profit Per Share Surpasses Its Benchmark in the Current Update; Trading Move - vinanet.vn
Nautilus Biotechnology urges new methods to address biological validation challenge in proteomics - Traders Union
Nautilus (NAUT) Watch: Closes 5.82% Higher at $0.90; Technical View: Traders Can Monitor the $0.85-$0.95 Range for the Current SessionSystematic Flow - vinanet.vn
Nautilus (NAUT) Watch: Closes 5.82% Higher at $0.90; Technical View: Traders Can Monitor the $0.85-$0.95 Range for the Current SessionOBV Breakout - siam.in
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Increase in Short Interest - MarketBeat
Nautilus Biotechnology Earnings Call Balances Promise and Risk - TipRanks
NAUT Q2 2026 Earnings: Narrower Loss Surprise Lifts Shares 22%Earnings Deceleration Risk - vinanet.vn
Perceptive Advisors group reports 9.1% Nautilus (NAUT) ownership in updated 13D/A - Stock Titan
Nautilus Biotechnology (NAUT) Slides 3.9% to $0.86, Approaching Key Support LevelLiquidity Order Flow - vinanet.vn
Nautilus Biotechnology (NAUT) Steadies Near $0.89 as Support HoldsMonthly Profile - careplusvn.com
Nautilus Biotechnology (NAUT) Steadies Near $0.89 as Support HoldsUpthrust Pattern - vinanet.vn
Nautilus Biotechnology (NAUT) Steadies Near $0.89 as Support HoldsGamma Flip Level - www.dars.gov.et
Nautilus Biotechnology (NAUT) Institutional Ownership 2026 - MarketBeat
Nautilus Biotechnology unveils new proteomics approach for dementia studies - Traders Union
Nautilus Biotechnology: A Contrarian Proteoformics Play After Recent Pullback (NAUT) - Seeking Alpha
Nautilus Biotechnology, Inc. Revenue Breakdown – NASDAQ:NAUT - TradingView
Nautilus Biotechnology Inc (NASDAQ: NAUT) Share Price, NAUT Stock News, NAUT Share Price & Updates - Kalkine
Nautilus Biotechnology Inc (NASDAQ: NAUT) Share Price, NAUT Stock News, NAUT Share Price & Updates - kalkine.ca
Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Rises By 74.6% - MarketBeat
Nautilus Biotechnology sets 31 July deadline for Iterative Mapping Grant Program applications - tradersunion.com
Nautilus Biotechnology Inc (NAUT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nautilus Biotechnology, Inc. 2026: Revenue $190K, EPS ($0.11) — 10-Q Summary - tradingview.com
Nautilus Biotechnology Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Nautilus Biotechnology beats Q2 2026 EPS forecast - Investing.com
Finanzdaten der Nautilus Biotechnology Inc-Aktie (NAUT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nautilus Biotechnology Inc-Aktie (NAUT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Patel Sujal M | CEO, President, and Secretary |
Mar 04 '26 |
Buy |
2.61 |
25,000 |
65,238 |
10,366,721 |
| Suzuki Kentaro | Chief Marketing Officer |
Nov 06 '25 |
Buy |
1.49 |
4,000 |
5,960 |
4,000 |
8.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):